home
Bringing New Horizons to Therapy

News & Media

General News

EDAP Highlights HIFU Expertise at 7th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer - Aug 26, 2014

EDAP TMS SA, announced its participation in the Seventh International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which took place in Los Angeles, August 21-23, 2014. The congress is a joint initiative of the University of Southern California (Los Angeles, USA), Duke University (Durham, USA) and AMC (Amsterdam, Netherlands).

EDAP Comments on FDA Panel Vote - Aug 5, 2014

 

EDAP TMS SA (Nasdaq:EDAP), today provided comments on the recent Gastroenterology and Urology Devices Panel (GUDP) vote on the safety, efficacy and risk/benefit ratio for the use of its Ablatherm-HIFU device for treatment of low-risk, localized prostate cancer.

EDAP's Ablatherm-HIFU FDA Panel Meeting Confirmed for July 30, 2014 - May 22, 2014

EDAP TMS SA,  today announced that the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee will review the Pre-Market Approval ("PMA") application for EDAP's Ablatherm-HIFU device for the treatment of localized prostate cancer on July 30, 2014.

European Association of Urology Recommends HIFU for Treatment of Localized Prostate Cancer - Apr 24, 2014

EDAP TMS, announced that HIFU for the primary treatment and salvage therapy of localized prostate cancer are recommended by the European Urology Association in its 2014 Guidelines released in April at the EAU's Annual Congress held inStockholm.

Reimbursement of HIFU for Prostate Cancer - Apr 21, 2014

Reimbursement of HIFU for Prostate Cancer in France

EDAP Completes FDA Q&A Session for Its Ablatherm-HIFU Pre-Market Approval Application - Mar 20, 2014

EDAP TMS, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step within the U.S. Food and Drug Administration ("FDA") review process.

EDAP TMS Delivers Focal One® Device for Focal Treatment of Prostate Cancer to Hospital in Poland - Feb 11, 2014

EDAP TMS announced today the installation of its Focal One device at the ESKULAP Private Hospital in Bydgoszcz, Poland.

Arnaud MONTEBOURG en visite à EDAP TMS - Oct 2, 2013

Arnaud MONTEBOURG, Ministre du redressement productif se rendra à la société EDAP TMS vendredi 4 octobre.

EDAP to Raise $12 Million in Registered Direct Offering - May 21, 2013

EDAP TMS SA , announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of $12 million of ordinary shares in the form of American Depositary Shares ("ADSs") at a price of $4.00 per share, with warrants attached.

EDAP's Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study - May 20, 2013
Third Long Term Study Published in 2013 Validates Ablatherm-HIFU as First Line Treatment of Prostate Cancer

EDAP's Ablatherm-HIFU Receives Two Best Poster Awards at 2013 American Urological Association Annual Meeting - May 14, 2013

  • Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer
  • HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting
  • Significant Interest in both HIFU and ESWL Technologies at EDAP Booth

EDAP Reports Fourth Quarter 2012 and Full Year Results Highlights - Apr 2, 2013
EDAP Reports Fourth Quarter 2012 and Full Year Results Highlights Record fourth quarter 2012 revenue of EUR 9.5 million (USD 12.3 million), up 25.3% year-over-year Record full year revenue of EUR 26.1 million (USD 33.6 million), up 16.9% year-over-year Record lithotripsy sales in 2012 PMA for Ablatherm®-HIFU for treatment of low risk, localized prostate cancer accepted by the FDA for filing on March 26, 2013

EDAP TMS Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application - Mar 28, 2013
Ablatherm® HIFU PMA Application Proceeds to Substantive Review EDAP TMS announced today that the U.S. Food and Drug Administration has provided a positive Filing Review Notification on the Company's Pre-Market Approval (PMA) application for its Ablatherm Integrated Imaging HIFU (High Intensity Focused Ultrasound) device for the treatment of low-risk, localized prostate cancer. The FDA conducted a filing review of EDAP's PMA, and found it to contain all of the information needed to proceed with the substantive review, in which the FDA will evaluate the safety and effectiveness of Ablatherm Integrated Imaging HIFU device, as well as EDAP's engineering, manufacturing and quality systems.

EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cance - Mar 14, 2013
Focal.One World Premiere at European Association of Urology Annual Congress. EDAP TMS SA, the global leader in therapeutic ultrasound, announced today the launch of Focal.One®, its new and innovative robotic HIFU device fully dedicated to focal therapy of prostate cancer. Focal.One® will be showcased for the first time at the European Association of Urology (EAU) 28th Annual Congress to be held in Milan, Italy on March 15-19, 2013 (booth # D41).

EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer - Feb 22, 2013

Munich Study Concludes 15 Year Outcome Data May Warrant Closing of Investigational Phase for HIFU

 EDAP TMS SA, the global leader in therapeutic ultrasound, announced today new long term data demonstrating high rates of both cancer-specific survival, and freedom from salvage therapy for patients treated with high-intensity focused ultrasound (HIFU) therapy.

EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period - Feb 8, 2013
Longest Retrospective Study of HIFU Patients to Date Published Confirms Benefits of Treatment

EDAP TMS Submits U.S. FDA Pre-Market Approval Application for Ablatherm(R)-HIFU for Treatment of Low Risk, Localized Prostate Cancer - Feb 1, 2013
EDAP TMS, the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to theU.S. Food and Drug Administration (FDA) onJanuary 31, 2013 for the Company's Ablatherm-HIFU (High Intensity Focused Ultrasound) for treatment of low risk, localized prostate cancer.

EDAP Appoints Experienced Lithotripsy Expert to Increase U.S. Sales - Oct 9, 2012

Strengthens Sales Team In Line With Strategy to Focus on U.S. Urology Market

 

EDAP TMS SA announced today the appointment of Bill Brown as U.S. based Senior Sales Manager. Mr. Brown joins EDAP's U.S. team to enhance the market penetration of the Company's Sonolith i-move extracorporeal lithotripsy (ESWL) system, expand U.S. lithotripsy sales initiatives, and begin to prepare for potential U.S. Food and Drug Administration (FDA) approval of the Company's Ablatherm-HIFU (High Intensity Focused Ultrasound) device.

EDAP TMS Retains Greenleaf Health as Strategic Advisor on U.S. FDA Submission - Aug 29, 2012

Strengthens Team for Final Stages of Ablatherm-HIFU Phase II/III Clinical Trial for Prostate Cancer

 

EDAP TMS SA today announced the retention of Greenleaf Health LLC, a full service regulatory consulting firm. Greenleaf Health will provide the Company with high-level strategic guidance regarding the final stages of its Ablatherm-HIFU (High Intensity Focused Ultrasound) ENLIGHT U.S. Phase II/III clinical trial for the indication of low risk, localized prostate cancer.

EDAP Completes Follow-Up Phase and Data Collection for FDA ENLIGHT Trial - Aug 17, 2012

EDAP TMS SA, today provided an update regarding its Ablatherm-HIFU (High Intensity Focused Ultrasound) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer. The trial is a multi-center U.S. Phase II/III clinical trial conducted under an Investigational Device Exemption (IDE) granted by the FDA. As previously announced, the last Ablatherm-HIFU patient was treated in June 2010. The two year anniversary of the last patient treated occurred on June 30, 2012, which marked the conclusion of the two year follow-up phase, and the Company confirms the completion of all two year follow-up visits.

Major shift in EDAP's strategy - May 16, 2012

Philippe Chauveau, EDAP's Chairman of the Board of Directors, said, "The Board has unanimously decided upon a major shift in EDAP's strategy and recommended, with immediate effect, that EDAP focus its efforts on the U.S. market where opportunities and priorities have been identified. This focus will involve immediate relocation to the U.S. of EDAP's CEO Marc Oczachowski."

Installation of a third Sonolith i-move lithotripter in the U.S - May 4, 2012
EDAP TMS SA announced today the installation of a third Sonolith i-move lithotripter in the U.S. The revolutionary lithotripter has been delivered to Allied Metro, a New York tri-state area partnership with more than 300 urologists.

Ablatherm® HIFU posters receive best poster awards at EAU 2012 in Paris - Feb 27, 2012
Among the 7 Ablatherm® HIFU poster presentations at EAU 2012 in Paris, 2 posters have been awarded "Best Posters" highlighting HIFU clinical data relevance.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "This confirms the recognition and acceptance of HIFU as one of the hottest topic in modern urology. It validates the support from the international urology community for Ablatherm-HIFU's positioning as a complement to surgery in addressing prostate cancer and proven ability to bring minimally invasive treatment to patients and urologists."

First Sonolith i-move now in use in the United States - Jan 4, 2012
New York Methodist Hospital (NYM) is the very first American hospital to acquire and use the Sonolith® i-move, the latest generation of Electroconductive lithotripter by EDAP TMS. "With the added conveniences of a handheld ultrasound probe to locate the stones, and the ability to generate consistent shock waves, we can treat lithotripsy patients with more precision and accuracy than ever before," said Grunberger, Head of Urology Division at NYM.

EDAP TMS partnership received €2.4 million grant for the developpement of new imaging technology - Aug 25, 2011
The development partnership, comprised of EDAP TMS, Edouard Herriot Hospital, and SuperSonic Imagine, received the highly competitive grant from Fonds Unique Interministerial (FUI), a French government fund for advancing technical innovation with short and midterm market applications. Marc Oczachowski, CEO quoted: "We are proud that our partnership won this grant, as it is another strong recognition and validation of EDAP as the leading player in the development of HIFU. [...] It will strengthen Ablatherm-HIFU's position as the premier gold standard for the non-invasive treatment of prostate cancer in line with current and future therapeutic strategies."  

Sonolith i-move lithotripter from EDAP TMS receives FDA 510(k) approval - Aug 5, 2011

Sonolith® i-move, the high-tech latest generation of Sonolith lithotripters just received FDA approval.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "This FDA clearance is a major milestone for EDAP and its U.S. business. The Sonolith i-move lithotripter is a technologically advanced device with modularity and mobile capability. We believe our Sonolith i-move is attractively positioned to take market share in the U.S., the second largest lithotripsy market worldwide. Our established U.S. sales and marketing organization has clearly identified potential customers within this dynamic lithotripsy market."

Join EDAP TMS on Facebook now! - Jul 12, 2011

You can now access all the EDAP TMS fresh news on Facebook. Join us now! www.facebook.com/edaptmscompany

Sonolith i-sys receives approval in Taiwan - Jun 21, 2011
Taiwan health authorities granted Sonolith® i-sys approval on the market. With the recent approval of Sonolith® i-move in Japan, this new approval is a major step towards broad acceptation of our lithotripters in Asia.

Sonolith i-move receives approval in Japan - Jun 21, 2011

EDAP TMS' latest lithotripter, Sonolith® i-move, receives market approval from the Japanese Health Authorities. This approval is a milestone for Sonolith® i-move as Japan is the first lithotripter market worldwide.  The full range of Sonolith® lithotripters is now available on the Japanese market enabling to cover the market needs with a high tech modular device (Sonolith® i-move) and a high-end device (Sonolith® i-sys).

Ablatherm now reimbursed in France under a special innovative therapies regimen - Feb 9, 2011
The French National Authority for Health (HAS - Haute Autorité de Santé) granted Ablatherm® HIFU treatment temporary reimbursement authorization under a special regimen for innovative therapies. More than 10 years after obtaining CE marking, the temporary reimbursement is a major step towards acceptation of HIFU as a standard treatment for prostate cancer.

First Ablatherm HIFU now treating prostate cancer patients in the Caribbean - Feb 8, 2011
CEDIMAT Center (Centro Diagnóstico, Medicina Avanzada y Telemedicina) in Santo Domingo, Dominican Republic is the first hospital of the Carribean to offer Ablatherm® HIFU treatment for prostate cancer. Dr. Octavio Cruz Piñeda has already performed 8 treatments with Stefan Thüroff, the most experiences Ablatherm® HIFU user with more than 2,000 patients treated. With the Ablatherm® HIFU treatment now available in the Caribbean, EDAP TMS reinforces the accessibility to Ablatherm® HIFU - minimally-invasive treatment for prostate cancer - in North America.

First Sonolith i-sys now in operation in South Africa - Jan 18, 2011
Pretoria Urology Hospital (PUH), the largest private urology hospital in South Africa, has installed and started treating patients with the first Sonolith i-sys lithotripter of the country. Only one year after the installation of the first Ablatherm HIFU device in South Africa in PUH, the installation of the first Sonolith i-sys is a major milestone in EDAP TMS' strategy to penetrate new markets.

Sonolith i-move receives Korean FDA approval - Dec 20, 2010
Less than one year after being launched in Europe, the Sonolith i-move, EDAP TMS' new modular lithotripter received Korean FDA (KFDA) approval. Korean is the second largest Asian market for lithotripsy behind Japan and this approval is an opportunity to gain market share and to reinforce our position as one of the leaders on the Korean market.

EDAP TMS receives 2010 Innovation Trophy for Sonolith i-move - Nov 23, 2010
The 2010 Rhône-Alpes Innovation Trophy ceremony awarded EDAP TMS the Product Innovation Trophy for its Sonolith® i-move, the revolutionnary lithotripter launched in 2010. This prize materializes our R&D efforts and our long tradition of innovation to bring safe, effective and minimally invasive treatment solutions for urological conditions.

HIFU for liver metastases from colorectal cancer - Nov 5, 2010

6 patients have successfully been treated with EDAP TMS' new HIFU device for liver cancer in the framework of a preliminary trial at Léon-Bérard center in Lyon, France. The first results confirm the feasibility of this innovative perioperative approach. This first step is very encouraging for this new application of HIFU technology developed jointly with the Inserm (French National Institute of Medical Research). Next step of the evaluation program on human is already scheduled for early 2011.

HIFU PLANET website available in Spanish, Italian and Dutsch - Sep 29, 2010

The website dedicated to patients information on prostate cancer and Ablatherm® HIFU treatment - HIFU PLANET - is now available in Spanish, Italian and Dutsch. Visit the websites at www.hifu-planet.eswww.hifu-planet.it and www.hifu-planet.nl . These versions of the new HIFU PLANET webiste adds up to the existing English and French versions. More linguistic versions will be available before the end of the year in order to make Ablatherm® HIFU treatment information available globally.

Favourable long-term outcomes of Ablatherm HIFU published in European Urology - Sep 21, 2010

A recent in-press publication in European Urology reported long-term clinical outcomes of 803 patients treated with Ablatherm® HIFU between 1993 and 2007. This study conducted by Dr. Sébastien Crouzet, the control of the disease was achieved with an 85% rate of negative biopsies and a biochemical disease free survival rate (Phoenix criteria) of 83% in low risk cancer patients. The durability of efficacy outcomes of robotic Ablatherm-HIFU in the treatment of localized prostate cancer is now established out to eight years.

HIFU PLANET website receives HonCode certification - Jul 16, 2010

HIFU Planet, our website dedicated to patient information on prostate cancer and Ablatherm® HIFU treatment just received HONcode certification.You can visit the websites www.hifu-planet.co.uk and www.hifu-planet.fr . HONcode is the oldest and the most used ethical and trustworthy code for medical and health related information available on Internet. We are proud to bear this internationnally renowned certification and to provide reliable information for patients.

Fist Sonolith® i-sys lithotripter in operation in Japan - Jul 8, 2010

After receiving approval from Japanese Health Authorities in March 2010, the first Sonolith i-sys lithotripter of the country has been successfully installed in Hitachinaka General Hospital in June. With this new installation, the Sonolith i-sys is now operating in 18 countries.

Now online: check out new HIFU PLANET website - Jun 8, 2010

The fully revamped HIFU PLANET website for prostate cancer patients looking for information and treatment centers with Ablatherm® HIFU is now online. Check it out on www.hifu-planet.co.uk and www.hifu-planet.fr

Sonolith i-move receives CE marking - Apr 13, 2010

EDAP TMS' latest modular lithotripter, Sonolith® i-move, is ready for prime-time at EAU congress in Barcelona after receiving CE marking. The device offers exclusive features including infrared stereo-vision system for real-time, three-dimensional ultrasound localization of urinary stones. With the addition of i-move to its range of lithotripters, EDAP TMS now covers all market segments with modern and high-tech systems.

EDAP TMS nominated for European Inventor Award 2010 - Mar 29, 2010

EDAP TMS is nominated along with Inserm for European Inventor Award 2010 for its work on Ablatherm HIFU for the minimally-invasive treatment of prostate cancer. The Award is presented annually by the European Patent Office (EPO) and European Commission honoring inventors in the field of science and technology .Years of research led to the first HIFU treatment for prostate cancer with Ablatherm in 1993. Up to date, more than 21,000 treatments have been performed worldwide with the device.

EDAP TMS symposium success in Washington D.C. - Mar 4, 2010

The 3rd International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer held in Washington D.C last week (February 24-27 2010) was a success for EDAP TMS with a highlight on Ablatherm® HIFU during a dedicated session. The pionneers of focal prostate cancer treatment with Ablatherm® presented promising clinical results to the audience composed of international prostate cancer experts.

A Grenoble, on traite les calculs avec le Sonolith i-sys sans anesthésie - Feb 3, 2010

France 3 Rhône-Alpes a consacré un reportage à l'unité de traitement des calculs urinaires du CHU de Grenoble dirigée par le Professeur Rambeaud et équipée avec le Sonolith® i-sys. Le CHU est pionnier dans le traitement des calculs urinaires sans aucune anesthésie rendu possible par la conception même du Sonolith® i-sys. Retrouvez le reportage en cliquant ici.

Journée de la prostate : vous avez le droit de savoir - Sep 15, 2009

Aujourd'hui, 15 Septembre 2009, c'est la journée de la prostate organisée dans le cadre de la semaine Européenne de l'Urologie. Cette journée de la prostate a pour but de sensibiliser tout un chacun au cancer de la prostate, son dépistage et ses traitements. A cette occasion, nous mettons en ligne notre nouveau dossier de presse en Français.

First Ablatherm® HIFU sold in Bolivia - Sep 11, 2009

EDAP TMS' first Ablatherm® HIFU system just got aquired by the Centro de Urologia Avanzada de la Clinica Incor Santa Cruz de la Sierra en Bolivia showing that the technology is penetrating more markets everyday.

Sonolith® i-sys receives FDA approval - Aug 24, 2009

EDAP TMS' high-end lithotripter Sonolith® i-sys has just been granted FDA approval. The device is now cleared for routine ESWL treatment in the USA. Sonolith® i-sys obtained CE mark in 2007 and has widely been adopted in Europe since. As all lithotripters from the Sonolith® range, the Sonolith® i-sys uses the exclusive Electroconductive technology for the management of urinary tract stones.

Ablatherm HIFU receives approval in Argentina - Jun 3, 2009
EDAP TMS just obtained approval from the Minitry of Health in Argentina for Ablatherm HIFU for the minimally-invasive treatment of localized prostate cancer. After being approved in Brazil earlier this year, the approval in Argentina shows that Ablatherm HIFU is gaining acceptance in South America. 

AURO publishes official guidelines regarding HIFU treatment - Apr 22, 2009
 In its latest recommendations, the AURO (Association of Italian Urologists) recommends Ablatherm® HIFU treatment as first-line treatment for localized prostate cancer. This publication coming a year after the publication of similar recommendations by the AFU (French Association of Urology) reinforces the growing place of HIFU in the treatment of prostate cancer.

Ablatherm® HIFU confirms success in South Africa - Apr 9, 2009

With 3 new treatment centers in Pretoria, Johannesburg and Durban, Ablatherm confirms its presence in South Africa. The country now counts 4 Ablatherm® HIFU treatment centers in major cities of the country.

Visit www.hifu-planet.com website to view the full list of Ablatherm® HIFU treatment centers.

EAU 2009 in Stockholm highlights HIFU - Apr 2, 2009
12.000 urologists attended this year's EAU congress in Stockholm which is a particularly successful edition for EDAP TMS. The EAU hosted the EDAP TMS sponsored HIFU symposium with 200 urologists attending from all over the world. Vincenzo Ficarra from University of Padua, Italy chaired the symposium around the theme of High Intensity Focused Ultrasound in the Modern Urology Practice.

Ablatherm® HIFU is now approved in Brazil - Feb 24, 2009

Ablatherm® HIFU is now approved in Brazil adding new outlooks for the technology.

With the recent installation of Ablatherm® HIFU in Mexico, the expansion of HIFU is on its way in Latin America.

First Ablatherm® HIFU system is now treating in Mexico. - Feb 12, 2009

The first Ablatherm® HIFU system was installed in Centro Médico Puerta de Hierro Hospital in Guadalajara this month and Dr. Jorge Gutierrez Aceves successfully performed the first treatments for localized prostate cancer. Mexico is the first country in Latin America to adopt Ablatherm® HIFU and the technology is now available in 26 countries worldwide.

3 Sonolith® i-sys systems are now in operation in Ecuador - Feb 6, 2009

EDAP TMS installed 3 Sonolith® i-sys systems in Ecuador this January and the first treatments were performed successfully by the teams of highly trained physicans. The 3 Sonolith® i-sys are installed in Quito, the capital of Equator, Guayaquil, the largest city of the country and Cuenca, the capital of Azuay province. The national and local Equatorian media widely relayed the installation of these high-tech ESWL systems.

India treats its first prostate cancer patients with Ablatherm® HIFU - Jan 29, 2009

On January 21st, the first Indian patients from Muljibhai Patel Urological Hospital in Nadiad, successfully received Ablatherm® HIFU treatment. The Ablatherm® installed at MPUH is the first one installed in India and the technology is now available in more than 25 countries.

Ultrasound & Therapy Community website is launched - Dec 11, 2008

EDAP TMS is proud to announce that launching of Ultrasound & Therapy Community website for Ablatherm® HIFU and Sonolith® users : "Continuous education and information network for EDAP TMS users". Designed to link Ablatherm® users via Internet, U&T Community website enables all users to have access to online training, videos, images and clinical publications all in one place.

Ablatherm® HIFU is now available in more than 200 centers. - Nov 10, 2008

In September 2008, the 200th Ablatherm® HIFU treatment center started treating patients for localized prostate cancer.

2 new Ablatherm® HIFU treatment centers in the Netherlands. - Oct 20, 2008

EDAP TMS is proud to announce the opening of 2 new Ablatherm® HIFU treatment centers in Zaandam and Roosendaal.

Ablatherm® is now operating in the Netherlands - Aug 26, 2008

EDAP TMS is proud to announce that Ablatherm® is now available in a new country. Amphia Ziekenhuis in Breda (Netherlands) is the first hospital of the country equipped with Ablatherm®.

New HIFU planet website launched in Germany - Jul 30, 2008

EDAP TMS launched a dedicated patient website for German prostate cancer patients seeking information on prostate cancer treatment. Visit HIFU planet at http://www.hifu-planet.de/ . Patients will find all information on Ablatherm® treatment and treatment centers addresses.

HIFU planet website in Turkish - Jul 30, 2008

EDAP TMS is proud to announce the launching of its patient website www.hifu-planet.com in Turkish. HIFU planet website is already available in English, French, German, Italian and Spanish and is dedicated to prostate cancer patients looking for information on Ablatherm® HIFU treatment. After only a few days of activity, 400 visits are recorded!

EDAP Expands Ablatherm-HIFU Business in Germany - Jul 15, 2008
Two Additional Centers Continue to Drive Revenue Per Procedure Adoption.

EDAP Highlights - Jun 30, 2008
Minimally Invasive Robotic HIFU Technology At British Association of Urological Surgeons Annual Meeting Launches "@-REGISTRY" Database in the United Kingdom.

EDAP Reports Publication Highlighting - Jun 10, 2008
EDAP Reports Publication Highlighting Ablatherm's Safety and Efficacy in Prostate Cancer
The French Association of Urology Defines the Indications for HIFU as Standard of Care for Prostate Cancer

EDAP Reports Q1 2008 - May 15, 2008
EDAP Reports First Quarter 2008 Financial Results

MD Anderson Cancer Center - May 13, 2008
EDAP Adds Premiere M.D. Anderson Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial

EDAP Conf Call Q1-08 - May 5, 2008
EDAP Announces Webcast and Conference Call of First Quarter 2008 Results

Print This Page

 

 

Financial news

Please go to Investors information section.